PRP vs Cortisone Injections: Evidence, Cost, and Which Is Better for Joint Pain
- Cortisone wins on short-term pain relief (1-4 weeks); PRP wins on 6-12 month outcomes in knee osteoarthritis and tendinopathy.
- Repeated cortisone injections carry documented risks of cartilage degradation and tendon weakening; PRP carries minimal tissue-harm risk.
- PRP costs $500-$2,000 per injection and is rarely covered by insurance; cortisone runs $100-$300 and is usually covered.
- For lateral epicondylitis and plantar fasciitis, PRP shows durable benefit at 12 months where cortisone shows rebound worse than baseline in some trials.
- The choice depends on your timeline, budget, and how many prior cortisone injections the joint has already received.
Your doctor offers a cortisone shot. You read about PRP online. Both go into a joint; beyond that, they work in almost opposite ways and have very different evidence profiles depending on the condition. The “which is better” question does not have a single answer, but the evidence gives us a clear framework for making the right call in specific situations.
This article breaks down the mechanisms, the head-to-head trial data, the cost difference, and the clinical logic behind choosing one over the other. For more on PRP protocols and applications, see our PRP Therapy Guide.
How They Work: Opposite Mechanisms
Cortisone (corticosteroid) injections work by suppressing the inflammatory response. They block prostaglandin synthesis, reduce vascular permeability, and inhibit immune cell activity at the injection site. The result is rapid, reliable pain relief in most acute inflammatory conditions. The effect is temporary because the underlying condition has not changed; the inflammation returns once the steroid clears.
PRP (platelet-rich plasma) works by amplifying the body’s own repair signals. A blood draw is centrifuged to concentrate platelets 3-8x above baseline. When injected, activated platelets release growth factors including PDGF, TGF-beta, IGF-1, VEGF, and EGF. These signals recruit reparative cells, stimulate collagen synthesis, and modulate local inflammation in a more selective way than corticosteroids. The response is slower to emerge but targets tissue repair rather than symptom suppression.
This mechanistic difference largely explains the diverging timelines seen in clinical trials: cortisone dominates at 4-8 weeks, PRP catches up and surpasses at 6-12 months.
Knee Osteoarthritis: Head-to-Head Evidence
The knee OA evidence base for this comparison is more developed than for most joint conditions.
Huang et al., 2019 (meta-analysis, Journal of Orthopaedic Surgery and Research, 14 RCTs, N=1,423): PRP produced significantly better WOMAC and VAS pain scores than corticosteroids at 3, 6, and 12 months. At 1 month, the difference was not significant. The authors concluded PRP is superior for medium and long-term outcomes in knee OA.
Kon et al., 2020 (American Journal of Sports Medicine, N=192 RCT): Compared single PRP injection to single corticosteroid injection in symptomatic knee OA. At 2 months, cortisone group had modestly better pain scores. At 6 and 12 months, PRP group had significantly better KOOS scores. Notably, the cortisone group showed a return to near-baseline pain by 6 months while PRP effects persisted.
The pattern across these trials is consistent: if your goal is getting through an acute flare or a specific event in the next few weeks, cortisone is the faster answer. If your goal is sustained pain reduction over the next year, PRP has better data.
Tendinopathy Evidence
Lateral Epicondylitis (Tennis Elbow)
This is where the PRP advantage is most clearly documented. Lateral epicondylitis is a tendinopathy (degeneration), not a classic inflammatory condition, which is why cortisone’s anti-inflammatory mechanism is a poor match for its biology.
Mishra et al., 2014 (American Journal of Sports Medicine, N=230 RCT) found PRP superior to whole blood at 24 weeks for recalcitrant lateral epicondylitis. Multiple systematic reviews confirm cortisone provides better short-term relief (4-8 weeks) but is associated with higher recurrence rates and worse outcomes than placebo or PRP at 6-12 months. This “cortisone rebound” pattern has been replicated consistently enough that many sports medicine physicians now view cortisone as contraindicated for chronic tendinopathy.
Plantar Fasciitis
The plantar fascia is another structure that responds poorly to repeated corticosteroid injection. Cortisone provides meaningful short-term relief, but fascia rupture and fat pad atrophy are documented complications of repeat injections. PRP trials for plantar fasciitis show comparable or superior outcomes at 6-12 months with a better safety profile for the tissue structure.
Mahindra et al., 2016 (Foot and Ankle International, N=60 RCT) showed PRP superior to corticosteroid at 6-month follow-up on VAS pain and AOFAS scores, with cortisone group showing more recurrence.
Rotator Cuff Tendinopathy
Evidence here is more mixed. Cortisone injections for subacromial impingement syndrome show reliable short-term benefit. PRP trials for rotator cuff tendinopathy show variable results, partly due to heterogeneity in PRP preparation protocols across studies. The 2021 Cochrane review found moderate-quality evidence favoring corticosteroids over PRP for short-term shoulder pain, but noted the evidence for 12-month outcomes remains uncertain. This is one area where cortisone is still competitive in the evidence base.
The Risks of Repeated Cortisone
A single cortisone injection carries low risk. The risks scale with frequency and anatomical location.
Cartilage damage: McAlindon et al., 2017 (JAMA, N=140 RCT) found that triamcinolone injections every 12 weeks for 2 years produced significantly greater cartilage volume loss on MRI compared to saline, without significant pain benefit at 2 years. This study significantly shifted how orthopedic and sports medicine specialists think about repeat cortisone in OA joints.
Tendon weakening: Corticosteroids inhibit tenocyte proliferation and collagen synthesis. Animal studies and case series show measurable reduction in tendon mechanical strength after repeated peritendinous injection. This is the structural basis for the cortisone rebound and rupture risk seen clinically.
Post-injection flare: Occurs in roughly 5-10% of patients, causing 24-48 hours of increased pain before the anti-inflammatory effect takes hold. Requires no treatment but should be warned about.
Systemic effects: Intra-articular cortisone can transiently raise blood glucose in diabetic patients, sometimes significantly (up to 50-100 mg/dL for 24-72 hours). Patients on insulin or at tight glycemic control should be aware of this and monitor accordingly.
Cost and Insurance Comparison
| Factor | Cortisone | PRP |
|---|---|---|
| Cost per injection | $100-$300 | $500-$2,000 |
| Typical treatment protocol | 1-3 injections per year | 1-3 injections (initial series) |
| Annual cost estimate | $100-$600 | $500-$6,000 |
| Insurance coverage | Usually covered | Rarely covered (experimental designation) |
| Duration of benefit (knee OA) | 4-8 weeks | 6-12+ months |
| Tissue safety with repeat use | Concerns with 3+ injections/year | No documented tissue harm |
| Procedure time | 5-10 minutes | 30-60 minutes (blood draw + centrifuge) |
On a cost-per-month-of-relief basis, the gap narrows considerably. A cortisone injection at $200 lasting 6 weeks costs about $33/month. A PRP injection at $1,000 lasting 10 months costs about $100/month. The raw cost difference is real, but the value calculation depends heavily on how long each actually works for you.
When Cortisone Is the Right Call
Cortisone makes sense in several specific situations. First, acute inflammatory flares (gout, acute bursitis, reactive arthritis) where rapid suppression of acute inflammation is the clinical goal. Second, pre-event pain management when a patient has a specific event in 2-4 weeks and needs reliable short-term relief. Third, early-stage conditions where a single injection may provide enough relief to allow physical therapy to take hold. Fourth, patients for whom the cost of PRP is genuinely prohibitive and the joint has not yet received multiple prior cortisone injections.
The key constraint: if a joint or tendon has already received 3+ cortisone injections, the structural risk calculus has shifted and PRP becomes a more defensible choice regardless of cost.
When to Choose PRP
PRP is the stronger choice when the goal is durable relief over 6-12 months rather than short-term suppression. Specifically: knee OA in patients who want to avoid or delay surgery; lateral epicondylitis or plantar fasciitis that has already been treated with 1-2 cortisone injections and relapsed; patients with diabetes where cortisone’s glycemic effect is a concern; younger patients where long-term joint health outweighs short-term convenience; and any tendinopathy where structural tissue health is a priority.
Combination Approaches
Some practitioners use a single cortisone injection to achieve rapid pain relief, followed 4-6 weeks later by PRP to address the underlying tissue repair. The logic is that cortisone reduces acute inflammation that might otherwise blunt the PRP growth factor response, while PRP addresses the longer-term repair. The evidence base for this sequence is limited to observational studies, but it is a reasonable clinical framework in selected patients.
What you should not do is give PRP immediately after cortisone. Corticosteroids impair platelet function and may reduce PRP efficacy if the two are given within 2-3 weeks of each other.
Evidence Grades Summary
| Condition | Cortisone Evidence | PRP Evidence | Preferred Long-Term |
|---|---|---|---|
| Knee osteoarthritis | Grade A (short-term) | Grade A (6-12 months) | PRP |
| Lateral epicondylitis | Grade B (short-term); Grade C (long-term) | Grade B (12 months) | PRP |
| Plantar fasciitis | Grade B (short-term) | Grade B (6-12 months) | PRP |
| Rotator cuff tendinopathy | Grade B (short-term) | Grade C (inconsistent) | Cortisone (short-term) |
| Acute bursitis/inflammatory flare | Grade A | Not indicated | Cortisone |
The Bottom Line
Cortisone is fast, cheap, and covered by insurance. For acute inflammation and short-term relief, it remains a legitimate and often appropriate tool. The problem arises when it becomes a repeated default for chronic degenerative conditions where it was never designed to work long-term and where the tissue harm from repeat use accumulates.
PRP is slower, more expensive, and not covered. But for knee OA and several tendinopathies, the 6-12 month data is meaningfully better. If you are managing a chronic condition and have already done the cortisone cycle, PRP is worth the investment for most patients who can afford it.
Related Reading
- Arthritis Guide: Rheumatoid Arthritis and Osteoarthritis
- Ehlers-Danlos Syndrome: Diagnostic Criteria, Types, and What the 2026 Updates Mean for You
- Osteoarthritis: What It Is, Why It Progresses, and How Regenerative Medicine Is Changing Treatment
- Plantar Fasciitis: Causes, Treatment, and Why Regenerative Medicine Might Be Your Best Option
- PRP Therapy: How Platelet-Rich Plasma Works and What It Treats
Frequently Asked Questions
Does PRP or cortisone work better for joint pain?
It depends on your timeframe. Cortisone gives rapid, reliable pain relief and dominates at 4 to 8 weeks, but the effect is temporary. PRP works more slowly because it targets tissue repair rather than symptom suppression, then catches up and surpasses cortisone at 6 to 12 months. For knee osteoarthritis, a review by Huang et al. (2019, 14 RCTs, 1,423 patients) found PRP produced significantly better WOMAC and VAS pain scores than corticosteroids at 3, 6, and 12 months.
How much do PRP and cortisone injections cost?
Cortisone runs about $100 to $300 per injection and is usually covered by insurance, giving an annual estimate of $100 to $600. PRP runs about $500 to $2,000 per injection and is rarely covered, with an annual estimate of $500 to $6,000. On a cost per month of relief basis the page estimates cortisone at roughly $33 per month and PRP at roughly $100 per month over a 10-month duration.
How long does it take each to work, and how long does relief last?
Cortisone acts quickly and lasts about 4 to 8 weeks for knee osteoarthritis. PRP is slower to emerge but lasts 6 to 12 months or more. In one RCT (Kon et al., 2020, 192 patients), cortisone scored better at 2 months while the cortisone group returned to near-baseline pain by 6 months, whereas PRP effects persisted and were significantly better at 6 to 12 months.
What are the side effects and risks of each?
With cortisone, 5 to 10 percent of patients get a post-injection flare of 24 to 48 hours of increased pain, and diabetic patients can see blood glucose rise up to 50 to 100 mg/dL for 24 to 72 hours. Repeated cortisone use is linked to tendon weakening, cartilage degradation, fascia rupture, and fat pad atrophy; one RCT (McAlindon et al., 2017, JAMA, 140 patients) found triamcinolone every 12 weeks for 2 years produced significantly greater cartilage volume loss on MRI. PRP carries minimal tissue-harm risk, with no documented tissue harm from repeat use.
Who should choose PRP and who should choose cortisone?
Cortisone suits acute inflammatory flares such as gout, acute bursitis, or reactive arthritis, pre-event pain management within 2 to 4 weeks, and cost-prohibitive patients with no prior cortisone injections. PRP suits knee osteoarthritis patients seeking 6 to 12 month relief, tennis elbow or plantar fasciitis that has relapsed after 1 to 2 cortisone injections, diabetic patients with glycemic concerns, younger patients prioritizing long-term joint health, and tendinopathies where structural tissue health matters.
Can PRP and cortisone be combined or given close together?
Do not give PRP immediately after cortisone; the page advises waiting 2 to 3 weeks because cortisone impairs platelet function. It also notes that if a joint or tendon has already received 3 or more cortisone injections, the structural risk has shifted and PRP becomes a more defensible choice regardless of cost.
